Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy.
Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy.
复制标题
DOI：
10.1002/art.34673
复制
发表时间：
2012-12
影响因子：
--
通讯作者：
Mammen, Andrew L.
中科院分区：
文献类型：
--
作者：
Werner, Jessie L.;Christopher-Stine, Lisa;Ghazarian, Sharon R.;Pak, Katherine S.;Kus, Jordan E.;Daya, Natalie R.;Lloyd, Thomas E.;Mammen, Andrew L.
抗HMGCR抗体见于他汀类药物相关免疫介导的坏死性肌病患者，较少见于未暴露于他汀类药物的自身免疫性肌病受试者。本研究的主要目的是确定抗HMGCR抗体水平与疾病活动性的相关性。在抗HMGCR阳性受试者中评估抗HMGCR水平、肌酸激酶（CK）水平和强度。在55例受试者中分析了访视1时抗体水平与CK和强度的相关性，其中40例暴露于他汀类药物。在12例他汀类药物暴露受试者和5例他汀类药物未暴露受试者中，使用5次连续访视的血清，研究了抗体水平、CK水平和强度的变化。抗体水平与第1次访视时的CK水平（p < 0.001）、臂力（p < 0.05）和腿部力量（p < 0.05）相关，但这些相关性仅在分层分析中的他汀类药物暴露患者中显著。治疗超过26.2 +/-12.6个月后，17名受试者的抗体水平下降（p < 0.05），手臂外展力量改善（p < 0.05）。当单独分析时，暴露于他汀类药物的受试者在治疗后抗体水平降低（p <0.01），CK水平降低（p < 0.001），手臂力量改善（p < 0.05），髋关节屈曲力量改善（p < 0.05）。任何受试者的抗HMGCR抗体水平均未正常化。在整个队列中，初始抗HMGCR水平与疾病活动指标相关;治疗后，抗体水平下降，臂力改善。他汀类药物暴露，但不是他汀类药物未暴露的受试者有显着改善CK和力量，表明他汀类药物暴露和未暴露的抗HMGCR患者之间的表型差异。
Anti-HMGCR antibodies are found in patients with statin-associated immune-mediated necrotizing myopathy and, less commonly, in statin-unexposed subjects with autoimmune myopathy. The main objective of this study is to define the association of anti-HMGCR antibody levels with disease activity. Anti-HMGCR levels, creatine kinase (CK) levels, and strength were assessed in anti-HMGCR positive subjects. Associations of antibody level with CK and strength at visit 1 were analyzed in 55 subjects, 40 of whom were statin-exposed. In 12 statin-exposed and 5 statin-unexposed subjects with serum from 5 serial visits, the evolution of antibody levels, CK levels, and strength was investigated. Antibody levels were associated with CK levels (p < 0.001), arm strength (p < 0.05), and leg strength (p < 0.05) at visit 1 but these associations were only significant amongst statin-exposed patients in stratified analyses. With treatment over 26.2 +/− 12.6 months, antibody levels declined (p < 0.05) and arm abduction strength improved (p < 0.05) in 17 subjects followed longitudinally. When analyzed separately, statin-exposed subjects developed decreased antibody levels (p < 0.01), decreased CK levels (p < 0.001), improved arm strength (p < 0.05), and improved hip flexion strength (p < 0.05) with treatment. Anti-HMGCR antibody levels did not normalize in any subject. In the entire cohort, initial anti-HMGCR levels correlated with indicators of disease activity; with treatment, antibody levels declined and arm strength improved. Statin-exposed but not statin-unexposed subjects had significant improvements in CK and strength, suggesting a phenotypic difference between statin-exposed and -unexposed anti-HMGCR patients.
登录
查看更多内容
影响因子：
4.7
作者：
Rider, Lisa G.;Koziol, Deloris;Giannini, Edward H.;Jain, Minal S.;Smith, Michaele R.;Whitney-Mahoney, Kristi;Feldman, Brian M.;Wright, Susan J.;Lindsley, Carol B.;Pachman, Lauren M.;Villalba, Maria L.;Lovell, Daniel J.;Bowyer, Suzanne L.;Plotz, Paul H.;Miller, Frederick W.;Hicks, Jeanne E.
通讯作者：
Hicks, Jeanne E.
影响因子：
--
作者：
Stone, Kerry B.;Oddis, Chester V.;Ascherman, Dana P.
通讯作者：
Ascherman, Dana P.
影响因子：
--
作者：
Benveniste, Olivier;Drouot, Laurent;Boyer, Olivier
通讯作者：
Boyer, Olivier
影响因子：
4.7
作者：
Mammen, Andrew L.;Pak, Katherine;Gaudet, Daniel
通讯作者：
Gaudet, Daniel
影响因子：
--
作者：
Mammen, Andrew L.;Chung, Tae;Christopher-Stine, Lisa;Rosen, Paul;Rosen, Antony;Doering, Kimberly R.;Casciola-Rosen, Livia A.
通讯作者：
Casciola-Rosen, Livia A.